A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group study 9617

Leukemia Research

Volumn 24, Issue 7, 2000, Pages 567-574

  Chauncey, Thomas R ^a,b,c   Rankin, Cathryn ^d   Anderson, Jeanne E ^e   Chen, I Ming ^f   Kopecky, Kenneth J ^d   Godwin, John E ^g   Kalaycio, Matt E ^h   Moore Jr , Dennis F ⁱ   Shurafa, Muhammad S ^j   Petersdorf, Stephen H ^a,b   Kraut, Eric H ^k   Leith, Catherine P ^f   Head, David R ^l   Luthardt, Frederick W ^b   Willman, Cheryl L ^f   Appelbaum, Frederick R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

Acute myelogenous leukemia; Drug resistance; Etoposide; mdr1; Mitoxantrone; P glycoprotein

Indexed keywords

CYCLOSPORIN DERIVATIVE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TOXICITY;

EID: 18844482235     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00024-2     Document Type: Article

References (51)

1. Godwin J.E., Kopecky K.J., Head D.R. et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood. 91:1998;3607-3615.
2. Rowe J.M., Andersen J.W., Mazza J.J. et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 86:1995;457-462.
3. Mayer R.J., Davis R.B., Schiffer C.A. et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl. J. Med. 331:1994;896-903.
4. Johnson P.R.E., LiuYin J.A. Acute myeloid leukaemia in the elderly: biology and treatment. Br. J. Haem. 83:1993;1-6.
5. Stone R.M., Mayer R.J. The approach to the elderly patient with acute myeloid leukemia. Hematol. Oncol. Clin. North Am. 7:1993;65-79.
6. Ryan D.H., Kopecky K.J., Head D. et al. Analysis of treatment failure in acute nonlymphocytic leukemia patients over 50 years of age: a Southwest Oncology Group Study. Am. J. Clin. Oncol. 15:1992;69-75.
7. Leith C.P., Kopecky K.J., Godwin J. et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study. Blood. 89:1997;3323-3329.
8. Willman C.L. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Sem. Hematol. 34(4):1997;25-33.
9. Head D.R. Revised classification of acute myeloid leukemia. Leukemia. 10:1996;1826-1831.
10. Willman C.L. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia. 1(10):1996;S33-S35.
11. Leith C.P., Chen I.M., Kopecky K.J. et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood. 86:1995;2329-2342.
12. Samdani A., Vijapurkar U., Grimm M.A. et al. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk. Res. 20:1996;175-180.
13. Guerci A., Merlin H.L., Missoun N. et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 85:1995;2147-2153.
14. Campos L., Guyotat D., Archimbaud E. et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 79:1992;473-476.
15. Filipits M., Pohl G., Stranzl T. et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood. 5:1998;1508-1513.
16. Filipits M., Suchomel R.W., Zöchbauer S. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res. 3:1997;1419-1425.
17. List A.F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin. Hematol. 5(34):1997;20-24.
18. List A.F., Spier C.S., Grogan T.M. et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 87:1996;2464-2469.
19. Advani R., Saba H.I., Tallman M.S. et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (valspodar). Blood. 93:1999;787-795.
20. Giaccone G., Linn S.C., Welink J. et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3:1997;2005-2015.
21. Fisher G.A., Lum B.L., Hausdorff J., Sikic B.I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer. 32A:1996;1082-1088.
22. Sonneveld P., Marie J.P., Huisman C. et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia. 10:1996;1741-1750.
23. List A.F., Spier C.M., Greer J. et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11:1993;1652-1660.
24. Sikic B.I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol. 11:1993;1629-1635.
25. Keller R.P., Altermatt H.J., Donatsch P. et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer. 51:1992;433-438.
26. Lum B.L., Kaubisch S., Yahanda A.M. et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10:1992;1635-1642.
27. Yahanda A.M., Alder K.M., Fisher G.A. et al. A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 10:1992;1624-1634.
28. Solary E., Witz B., Caillot D. et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 88:1996;1198-1205.
29. Miller T.P., Grogan T.M., Dalton W.S. et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J. Clin. Oncol. 9:1991;17-24.
30. Lee E.J., George S.L., Caligiuri M. et al. Parallel phase I studies of daunomycin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myelogenous leukemia: results of Cancer and Leukemia Group B study 9420. J. Clin. Oncol. 17:1999;2831-2839.
31. List A.F., Kopecky K.J., Willman C.L. et al. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: a Southwest Oncology Group (SWOG) study. Blood. 92:1998;312a.
32. Kornblau S.M., Estey E., Madden T. et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol. 15:1997;1796-1802.
33. Sonneveld P., Lowenberg B., Vossebeld P. et al. Dose finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ara-C in untreated elderly patients with acute myeloid leukemia. Blood. 90:1997;507a.
34. Sonneveld P., Durie B.G.M., Lokhorst H.M. et al. Modulation of multidrug resistance multiple myeloma by cyclosporin. Lancet. 340:1992;255-259.
35. Watanabe T., Tsuge H., Oh-Hara T. et al. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 34:1995;235-241.
36. Investigators Brochure, PSC-833, Sandoz Pharmaceuticals Corp., December, 1993.
37. Friche E., Jensen P.B., Nissen N.I. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother. Pharmacol. 30:1992;235-237.
38. Boesch D., Gaveriaux C., Jachez B. et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51:1991;4226-4233.
39. Twentyman P.R., Bleehen N.M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer. 27:1991;1639-1642.
40. Twentyman P.R. Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br. J. Cancer. 57:1988;254-258.
41. Bow E.J., Sutherland J.A., Kilpatrick M.G. et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J. Clin. Oncol. 14:1996;1345-1352.
42. Boote D.J., Dennis I.F., Twentyman P.R. et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14:1996;610-618.
43. Ho A.D., Lipp T., Ehninger G. et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia-an active and well-tolerated regimen. J. Clin. Oncol. 6:1988;213-217.
44. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest. New Drugs. 10:1992;239-253.
45. Cheson B.D., Cassileth P.A., Head D.R. et al. Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813-819.
46. Leith C.P., Kopecky K.J., Chen I.M. et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 94:1999;1086-1099.
47. Beck W.T., Grogan T.M., Willman C.L. et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56:1996;3010-3020.
48. Dastugue N., Payen C., Lafage-Pochitaloff M. et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 9:1995;1491-1498.
49. Grimwade D., Walker H., Oliver F. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 92:1998;2322-2333.
50. Tallman M., Lee E., Sikic B.I. et al. Mitoxantrone, etoposide and cytarabine plus cyclosporine in patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 85:1999;358-367.
51. Erlichman C., Moore M., Thiessen J.J. et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 53:1993;4837-4842.